Physician profile
Vinay Thohan
NPI 1184650798
$164,164.10
in general payments reported to CMS, 2019-2025
27 companies · $17K in 2025
The $17K reported for 2025 was more than what 83% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,391 · 2020: $22K · 2021: $38K · 2022: $38K · 2023: $23K · 2024: $23K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Food and Beverage: $7,555 · Travel and Lodging: $3,561 · Consulting Fee: $300 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,096.00 |
| Food and Beverage | $7,555.02 |
| Travel and Lodging | $3,561.30 |
| Consulting Fee | $300.00 |
| Education | $108.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $73,585.82 | 2019-2025 | Jardiance |
| Pfizer INC. | $45,104.77 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $15,710.44 | 2020-2025 | Optimizer, Optimizer |
| Lilly USA, LLC | $9,900.00 | 2020-2025 | Jardiance |
| Abbott Laboratories | $9,552.12 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Navitor |
| E.R. Squibb & Sons, L.L.C. | $5,506.74 | 2022-2025 | Camzyos, Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $1,346.25 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $817.25 | 2023-2025 | Opsumit, Uptravi |
| Abiomed | $593.31 | 2020-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $391.86 | 2019-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $311.41 | 2023-2025 | Winrevair, Verquvo |
| Astrazeneca Pharmaceuticals Lp | $170.86 | 2023-2025 | Wainua, Farxiga |
| Cvrx, INC. | $151.61 | 2024-2025 | Barostim Neo System |
| Amgen INC. | $147.41 | 2019-2020 | |
| Sandoz INC. | $143.78 | 2021-2024 | Treprostinil |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $138.13 | 2019 | |
| Bridgebio Pharma, INC. | $134.25 | 2025 | Attruby |
| Medtronic, INC. | $97.85 | 2024 | Corevalve Evolut R |
| United Therapeutics Corporation | $73.55 | 2023-2024 | Tyvaso |
| Atricure, INC. | $64.63 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $47.38 | 2022-2023 | Amvuttra |
| Novartis Pharmaceuticals Corporation | $43.76 | 2023 | |
| Cardiovascular Systems INC. | $32.83 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $26.50 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $26.46 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $24.28 | 2023 | |
| Novo Nordisk INC | $20.85 | 2024 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinay Thohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.